IL-8 Inhibitors for Interstitial Cystitis and Overactive Bladder
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for interstitial cystitis/painful bladder syndrome (IC/PBS) and overactive bladder (OAB) are insufficient due to limited efficacy and side effects, and there is a need for more effective and safer medicaments.
Innovation Solution
The use of IL-8 inhibitor compounds, such as antibodies or small molecules, to treat and prevent IC/PBS and/or OAB, including cases induced by anticancer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (oral pharmacologic agents, intravesical therapies) are used for IC/PBS and OAB, then some therapeutic effect is achieved, but efficacy is limited and side effects occur
Solution Approach 1:
The patent extracts and targets the specific inflammatory pathway mediated by IL-8 and its receptors CXCR1/CXCR2 in the bladder tissue. By using IL-8 inhibitors or CXCR1/CXCR2 antagonists, the treatment specifically blocks the harmful inflammatory signaling without affecting other physiological processes, thereby improving efficacy while reducing side effects compared to broad-spectrum anti-inflammatory agents.
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific anti-inflammatory or anticholinergic effects to specific blockade of IL-8 signaling pathway. This targeted approach modifies the mechanism of action to achieve better therapeutic outcomes with reduced off-target effects, addressing the contradiction between efficacy and side effects.
2Ease of operation
If available treatments are used for IC/PBS and OAB, then some symptoms are relieved, but overall treatment effectiveness is insufficient
Solution Approach 1:
The patent introduces IL-8 inhibitors or CXCR1/CXCR2 antagonists as intermediary substances that specifically block the inflammatory signaling pathway in the bladder. These intermediaries intervene in the disease process by preventing IL-8 from binding to its receptors, thereby effectively reducing inflammation and improving treatment effectiveness beyond what current therapies achieve.
3Object-affected harmful factors
If broad-spectrum anti-inflammatory agents are used, then general inflammation is reduced, but specificity to IC/PBS and OAB pathology is insufficient
Solution Approach 1:
The patent applies local quality by targeting the specific IL-8/CXCR1/CXCR2 signaling pathway that is locally upregulated in IC/PBS and OAB bladder tissue. Rather than using systemic anti-inflammatory agents that affect the entire body, the treatment specifically addresses the pathological inflammation in the bladder through pathway-specific inhibition, achieving both anti-inflammatory effect and pathology specificity.
Data Source
AI summary
The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB), also including IC/PBS and/or OAB induced by anticancer therapy. Methods of treatment and/or prevention, combinations and kits comprising said IL-8 inhibitors are also covered therein.